Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.32M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
362K
-
Shares change
-
+362K
-
Total reported value, excl. options
-
$3.57M
-
Value change
-
+$3.57M
-
Number of buys
-
18
-
Price
-
$9.82
Significant Holders of PIERIS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value (PIRS) as of Q2 2024
18 filings reported holding PIRS - PIERIS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value as of Q2 2024.
PIERIS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value (PIRS) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 362K shares
of 1.32M outstanding shares and own 27.47% of the company stock.
Largest 10 shareholders include BVF INC/IL (258K shares), Lynx1 Capital Management LP (43.5K shares), BlackRock Inc. (13K shares), RENAISSANCE TECHNOLOGIES LLC (11.5K shares), VANGUARD GROUP INC (11.3K shares), ACADIAN ASSET MANAGEMENT LLC (10.8K shares), GEODE CAPITAL MANAGEMENT, LLC (10.6K shares), UBS Group AG (1.73K shares), CITIGROUP INC (1.11K shares), and Tower Research Capital LLC (TRC) (334 shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.